Expert Opinion on Biological Therapy, Volume 22, Issue 11 (2022)

Browse this journal
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Expert Opinion on Biological Therapy, Volume 22, Issue 11 (2022)

See all volumes and issues
Vol 24, 2024 Vol 23, 2023 Volume 22, 2022 Vol 21, 2021 Vol 20, 2020 Vol 19, 2019 Vol 18, 2018 Vol 17, 2017 Vol 16, 2016 Vol 15, 2015 Vol 14, 2014 Vol 13, 2013 Vol 12, 2012 Vol 11, 2011 Vol 10, 2010 Vol 9, 2009 Vol 8, 2008 Vol 7, 2007 Vol 6, 2006 Vol 5, 2005 Vol 4, 2004 Vol 3, 2003 Vol 2, 2002 Vol 1, 2001
Download citations Download PDFs Download issue

Drug Evaluation

Article
Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan
Kentaro Harada, Shun Yamamoto & Ken Kato
Pages: 1333-1338
Published online: 20 Oct 2022
AbstractforPembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan | Full Text | References | PDF (791.8 KB) | EPUB
  • 1560 Views
  • 1 CrossRef citations
  • 0Altmetric
Open Access

Key Paper Evaluation

Article
The ULTIMATE trials: are there advantages of ublituximab over teriflunomide in relapsing multiple sclerosis?
Sheila A Doggrell
Pages: 1339-1343
Published online: 03 Nov 2022
AbstractforThe ULTIMATE trials: are there advantages of ublituximab over teriflunomide in relapsing multiple sclerosis? | Full Text | References | PDF (189.6 KB) | EPUB
  • 236 Views
  • 0 CrossRef citations
  • 0Altmetric

Special Report

Article
Sargramostim in acute radiation syndrome
Hillard M Lazarus, John McManus & Robert Peter Gale
Pages: 1345-1352
Published online: 06 Nov 2022
AbstractforSargramostim in acute radiation syndrome | Full Text | References | PDF (348.7 KB) | EPUB
  • 1165 Views
  • 2 CrossRef citations
  • 0Altmetric
Open Access

Perspective

Article
Original antigen sin and COVID-19: implications for seasonal vaccination
Matthew W. McCarthy
Pages: 1353-1358
Published online: 18 Oct 2022
AbstractforOriginal antigen sin and COVID-19: implications for seasonal vaccination | Full Text | References | PDF (199.2 KB) | EPUB
  • 319 Views
  • 1 CrossRef citations
  • 0Altmetric

Review

Review
Locked and loaded: engineering and arming oncolytic adenoviruses to enhance anti-tumor immune responses
Shao-Chia Lu & Michael A Barry
Pages: 1359-1378
Published online: 09 Nov 2022
AbstractforLocked and loaded: engineering and arming oncolytic adenoviruses to enhance anti-tumor immune responses | Full Text | References | PDF (7.1 MB) | EPUB
  • 1393 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access
Article
Antibody therapeutics for epithelial ovarian cancer
Mason Ruiz, Ningyan Zhang, Anil K Sood & Zhiqiang An
Pages: 1379-1391
Published online: 05 Nov 2022
AbstractforAntibody therapeutics for epithelial ovarian cancer | Full Text | References | PDF (1.7 MB) | EPUB
  • 271 Views
  • 0 CrossRef citations
  • 0Altmetric
Review
Transitioning immunotherapy in neuromyelitis optica spectrum disorder – when and how to switch
Anastasia Vishnevetsky, Tamara B. Kaplan & Michael Levy
Pages: 1393-1404
Published online: 14 Nov 2022
AbstractforTransitioning immunotherapy in neuromyelitis optica spectrum disorder – when and how to switch | Full Text | References | PDF (333.5 KB) | EPUB
  • 252 Views
  • 0 CrossRef citations
  • 0Altmetric
Review
Cell homing strategy as a promising approach to the vitality of pulp-dentin complexes in endodontic therapy: focus on potential biomaterials
Elaheh Dalir Abdolahinia, Zahra Safari, Sayed Soroush Sadat Kachouei, Ramin Zabeti Jahromi, Nastaran Atashkar, Amirreza Karbalaeihasanesfahani, Mahdieh Alipour, Nastaran Hashemzadeh, Simin Sharifi & Solmaz Maleki Dizaj
Pages: 1405-1416
Published online: 08 Nov 2022
AbstractforCell homing strategy as a promising approach to the vitality of pulp-dentin complexes in endodontic therapy: focus on potential biomaterials | Full Text | References | PDF (2.1 MB) | EPUB
  • 184 Views
  • 0 CrossRef citations
  • 0Altmetric

Original Research

Article
Analytical comparability demonstrated for an IgG4 molecule, inclacumab, following transfer of manufacturing responsibility from Roche to Global Blood Therapeutics
Radu Mihaila, Dipali Ruhela, Lifang Xu, Sandra Joussef, Xin Geng, Jianxia Shi, Andrea S. Kim, Wendy Yares, Kevin Furstoss & Kent Iverson
Pages: 1417-1428
Published online: 09 Nov 2022
AbstractforAnalytical comparability demonstrated for an IgG4 molecule, inclacumab, following transfer of manufacturing responsibility from Roche to Global Blood Therapeutics | Full Text | References | PDF (442.8 KB) | EPUB | Supplemental
  • 1395 Views
  • 1 CrossRef citations
  • 0Altmetric
Open Access

Explore articles

Explore the most recently published articles

Understanding patient variability to biologic treatments in inflammatory bowel disease
Ahmad Z Al Meslamani
Editorial | Published online: 24 May 2024
Free Access
Next-generation CD40 agonists for cancer immunotherapy
Hampus Andersson et al.
Review Article | Published online: 23 May 2024
Open Access
Non-TNF biologics and their biosimilars in rheumatoid arthritis
Tsz Ching Mok et al.
Review Article | Published online: 22 May 2024
Could siRNA therapeutics change the way we treat dyslipidemia?
Peter E. Penson et al.
Editorial | Published online: 22 May 2024
Free Access
View all latest articles